## 4 Results
\begin{table}
\begin{tabular}{c c c c c c} \hline
**Classifiers** & **Parameters** & **Malignant** & **Benign** & **Control** & **Average** \\ \hline DT & precision & 43.8 & 83.3 & 75 & 67.4 \\ \cline{2-6}  & sensitivity & 70 & 50 & 60 & 60 \\ \cline{2-6}  & specificity & 55 & 95 & 90 & 80 \\ \cline{2-6}  & accuracy & 60 & 60 & 60 & 60 \\ \cline{2-6}  & F1-score & 53.8 & 62.5 & 66.7 & 61 \\ \hline SVM & precision & 90 & 44.4 & 0 & 44.8 \\ \cline{2-6}  & sensitivity & 90 & 80 & 0 & 56.7 \\ \cline{2-6}  & specificity & 95 & 50 & 90 & 78.3 \\ \cline{2-6}  & accuracy & 56.7 & 56.7 & 56.7 & 56.7 \\ \cline{2-6}  & F1-score & 90 & 57.1 & 0 & 0 \\ \hline KNN & precision & 42.9 & 71.4 & 55.6 & 56.6 \\ \cline{2-6}  & sensitivity & 60 & 50 & 50 & 53.3 \\ \cline{2-6}  & specificity & 60 & 90 & 80 & 76.7 \\ \cline{2-6}  & accuracy & 53.3 & 53.3 & 53.3 & 53.3 \\ \cline{2-6}  & F1-score & 50 & 58.8 & 52.6 & 53.8 \\ \hline \end{tabular}
\end{table} 
Table 2: Performance evaluation, including precision, sensitivity, specificity, accuracy, and F1-score for the DT, SVM, and KNN classifiers to show the blood hormones performance from normal subjects, benign patients, and malignant patients. Table 3 shows the effectiveness of the blood hormones in normal, benign, and malignant subjects demonstrated through the use of performance assessment criteria such as precision, sensitivity, specificity, accuracy, and F1-score for the DT, SVM, and KNN classifiers using the FA dimensionality reduction technique. \begin{table}
\begin{tabular}{c c c c c c} \hline
**Classifiers** & **Parameters** & **Malignant** & **Benign** & **Control** & **Average** \\ \hline DT & precision & 75 & 81.8 & 85.7 & 80.8 \\ \cline{2-6}  & sensitivity & 90 & 90 & 60 & 80 \\ \cline{2-6}  & specificity & 85 & 90 & 95 & 90 \\ \cline{2-6}  & accuracy & 80 & 80 & 80 & 80 \\ \cline{2-6}  & F1-score & 81.8 & 85.7 & 70.6 & 79.4 \\ \hline SVM & precision & 55.6 & 100 & 100 & 85.2 \\ \cline{2-6}  & sensitivity & 100 & 60 & 60 & 73.3 \\ \cline{2-6}  & specificity & 60 & 100 & 100 & 86.7 \\ \cline{2-6}  & accuracy & 73.3 & 73.3 & 73.3 & 73.3 \\ \cline{2-6}  & F1-score & 71.4 & 75 & 75 & 73.8 \\ \hline KNN & precision & 70 & 70 & 60 & 66.7 \\ \cline{2-6}  & sensitivity & 70 & 70 & 60 & 66.7 \\ \cline{2-6}  & specificity & 85 & 85 & 80 & 83.3 \\ \cline{2-6}  & accuracy & 66.7 & 66.7 & 66.7 & 66.7 \\ \cline{2-6}  & F1-score & 70 & 70 & 60 & 66.7 \\ \hline \end{tabular}
\end{table} 
Table 3: Performance evaluation, including precision, sensitivity, specificity, accuracy, and F1-score, for the DT, SVM, and KNN classifiers using the FA dimensionality reduction technique to show the blood hormones performance from normal subjects, benign patients, and malignant patients. Figure 2: Confusion matrices for the DT, SVM, and KNN classifiers to demonstrate the blood hormones performance from the normal subjects, benign patients, and malignant patients. The confusion matrix for identifying normal subjects, benign patients, and malignant patients based on the blood levels of P, T, C, and HCG is depicted in Figure 3, and it was created with statistical features after applying the FA dimensionality reduction techniques with the KNN, SVM, and DT classifiers with FA in that order. On the diagonal, the correct recognition is seen, whereas the off-diagonal areas represent the incorrect substitutions. Figure 3 displays the percentage of correctly identified data produced by the DT, SVM, and KNN classifiers with FA using blood level hormones. The accuracy of the DT, SVM, and KNN was 80%, 73.33%, and 66.67%, respectively. As a result, nine of the malignant patients, nine of the benign patients, and six of the control subjects were correctly identified using the DT, whereas one of the malignant patients was incorrectly classified as a benign patient. Moreover, one of the benign patients was incorrectly classified as a malignant patient, and four of the control subjects were incorrectly classified as three malignant patients and one benign patient.